| Description | BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM). BJE6-106 induces caspase-dependent apoptosis with tumor-specific effect. |
| In vitro | BJE6-106 (0.2 μM, 0.5 μM; 6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells. BJE6-106 (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations. BJE6-106 (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing JNK, MKK4, and H2AX activation at different times in SBcl2 cells. |
| Target activity | PKCα:50 μM, PKCδ:0.05 μM |
| Synonyms | B106 |
| molecular weight | 381.47 |
| Molecular formula | C26H23NO2 |
| CAS | 1564249-38-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Takashima A,et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9(4):1003-14. |